GRTX Live signals | Maximize Profits with Getagraph.com

Live Chart Being Loaded With Signals

Commentary (18 Apr 2024 @ 16:00):

Galera Therapeutics, Inc., a clinical stage biopharmaceutical company, focuses on the development and commercialization of therapeutics for the transformation of radiotherapy in cancer...

Stats
Today's Volume	3.76M
Average Volume	1.98M
Market Cap	10.12M
EPS	$0 ( 2024-03-25 )
Next earnings date	( $0 ) 2024-05-09
Last Dividend	$0 ( N/A )
Next Dividend	$0 ( N/A )
P/E	-0.140
ATR14	$0 (0.00%)

Insider Trading

Date	Person	Action	Amount	type
2023-12-31	Altamont Pharmaceutical Holdings, Llc	Buy	0
2024-02-08	Schneid Yair	Buy	150 000	Common Stock
2024-02-07	Schneid Yair	Buy	150 000	Common Stock
2024-02-07	Schneid Yair	Buy	25 000	Common Stock
2024-02-06	Schneid Yair	Buy	25 000	Common Stock

INSIDER POWER
99.55
Last 95 transactions
Buy: 5 055 072 \| Sell: 1 341 015

Volume Correlation

Long: -0.04 (neutral)

Short: -0.93 (very strong negative)

Signal:(53.368) Neutral

Galera Therapeutics Inc Correlation

10 Most Positive Correlations
LIAN	0.848
IMAB	0.843
MEUSW	0.842
PXLW	0.841
ADXN	0.839
LEGO	0.833
FORA	0.828
VYGR	0.814

10 Most Negative Correlations

Did You Know?

Correlation is a statistical measure that describes the relationship between two variables. It ranges from -1 to 1, where -1 indicates a perfect negative correlation (as one variable increases, the other decreases), 1 indicates a perfect positive correlation (as one variable increases, the other increases), and 0 indicates no correlation (there is no relationship between the variables).

Correlation can be used to analyze the relationship between any two variables, not just stocks. It's commonly used in fields such as finance, economics, psychology, and more.

Galera Therapeutics Inc Correlation - Currency/Commodity

-0.01
( neutral )

-0.05
( neutral )

0.00
( neutral )

0.14
( neutral )

Galera Therapeutics Inc Financials

Annual	2023
Revenue:	$0
Gross Profit:	$-259 000 (0.00 %)
EPS:	$-1.330

Q4	2023
Revenue:	$0
Gross Profit:	$-215 000 (0.00 %)
EPS:	$-0.100

Q3	2023
Revenue:	$0
Gross Profit:	$-12 000.00 (0.00 %)
EPS:	$-0.330

Q2	2023
Revenue:	$0
Gross Profit:	$-12 000.00 (0.00 %)
EPS:	$-0.480

Financial Reports:

No articles found.

Galera Therapeutics Inc

Galera Therapeutics, Inc., a clinical stage biopharmaceutical company, focuses on the development and commercialization of therapeutics for the transformation of radiotherapy in cancer. The company's lead product candidate is avasopasem manganese (GC4419), a small molecule superoxide dismutase mimetic, which has completed Phase III clinical trial for the treatment of radiotherapy induced severe oral mucositis in patients with head and neck cancer (HNC); in Phase IIa clinical trial for the treatment of radiotherapy-induced esophagitis in patients with lung cancer; and in Phase IIa clinical trial for patients with HNC undergoing standard-of-care radiotherapy. It is also involved in developing GC4711, a superoxide dismutase mimetic product candidate, which is in Phase I/II clinical trial in combination with stereotactic body radiation therapy (SBRT) in patients with non-small cell lung cancer and locally advanced pancreatic cancer. The company was incorporated in 2012 and is headquartered in Malvern, Pennsylvania.